Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 12:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Atara (ATRA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/22/2026.
April 02, 2026 12:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Inovio (INO) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/7/2026.
April 02, 2026 12:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for uniQure N.V. (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/13/2026.
April 02, 2026 12:00 ET | Source: Regeneron Pharmaceuticals, Inc.

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing...
April 02, 2026 11:58 ET | Source: Research and Markets

Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapy Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, including...
April 02, 2026 11:55 ET | Source: Kessler Topaz Meltzer & Check LLP

NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.

Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass...
April 02, 2026 11:49 ET | Source: Research and Markets

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Intelligence Report 2026-2030: Industry Growth Driven by Personalized Treatment Adoption

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a...
April 02, 2026 11:30 ET | Source: SNS Insider pvt ltd

Test Strip Market Set to Hit USD 22.91 Billion by 2035, Driven by Rising Diabetes Burden – SNS Insider

Austin, United States, April 02, 2026 (GLOBE NEWSWIRE) -- Test Strip Market Size & Growth Analysis: According to SNS Insider, The Test Strip Market size is valued at USD 14.79 Billion in 2025...
April 02, 2026 10:49 ET | Source: Faruqi & Faruqi LLP

QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options If you purchased or...
April 02, 2026 10:47 ET | Source: Research and Markets

Metastatic Lung Adenocarcinoma Treatment Market Outlook Report 2026-2030: Targeted Therapies Fuel Growth, with Revenues Reaching $5 Billion by 2030

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Metastatic Lung Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The metastatic lung...